9215 Brown Deer Road
5 articles with Lassen Therapeutics
Lassen Therapeutics Announces Collaboration with Cedars Sinai Medical Center to Study the Role of IL-11 Signaling and Inhibition in Preclinical Models of Lung Fibrosis
Goal is to generate proof of principle and mechanistic understanding of the efficacy of antibodies targeting IL-11 receptor in idiopathic pulmonary fibrosis
Lassen Therapeutics Announces Collaboration with the Olivia Newton-John Cancer Research Institute to Study the Role of IL-11 Signaling and Inhibition in Preclinical Models of Breast Cancer
Lassen Therapeutics , a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia.
Lassen Therapeutics , a biotech company developing innovative antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced the formation of its scientific advisory board. Lassen’s lead molecule, LASN01, is a best-in-class monoclonal antibody targeting the interleukin-11 (IL-11) receptor. The newly formed SAB will work closely with Lassen’s leadership team to further advance research and develop
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology.
Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round. The round was led by Frazier Healthcare Partners with participation from Alta Partners and Longwood Fund.